SAB Biotherapeutics, Inc., (SABS) Social Stream
SAB BIOTHERAPEUTICS INC (SABS) Price Targets From Analysts
Use the tables below to see what analysts covering SAB BIOTHERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-23 | 4 | $23 | $16.5 | $18.625 | $0.701 | 2556.92% |
| 2021-12-02 | 4 | $23 | $16.5 | $19.375 | $0.701 | 2663.91% |
| 2022-03-31 | 4 | $23 | $9 | $16.375 | $0.701 | 2235.95% |
| 2022-04-04 | 4 | $23 | $9 | $14.625 | $0.701 | 1986.31% |
| 2022-04-06 | 4 | $23 | $9 | $14.1 | $0.701 | 1911.41% |
| 2022-05-15 | 4 | $23 | $7 | $13.35 | $0.701 | 1804.42% |
| 2022-05-17 | 4 | $23 | $7 | $12.85 | $0.701 | 1733.1% |
| 2022-08-11 | 4 | $12.4 | $3 | $7.1 | $0.701 | 912.84% |
| 2022-08-23 | 4 | $9 | $3 | $6.062 | $0.701 | 764.76% |
| 2022-11-16 | 2 | $9 | $3 | $6.062 | $0.701 | 764.76% |
| 2022-11-21 | 2 | $9 | $3 | $5.75 | $0.701 | 720.26% |
| 2023-01-18 | 3 | $9 | $3 | $5.4 | $0.701 | 670.33% |
The Trend in the Analyst Price Target
SABS's average price target has moved down $1.7 over the prior 160 days.
Over the past 46 weeks, SABS's average upside potential has been 483.93%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-15 | 4 | 23.0 | 7 | 13.35 | 1.99 | 570.85% |
| 2022-08-11 | 4 | 12.4 | 3 | 7.10 | 1.12 | 533.93% |
| 2022-11-21 | 3 | 9.0 | 3 | 5.75 | 1.09 | 427.52% |
| 2022-11-21 | 2 | 9.0 | 3 | 5.75 | 1.09 | 427.52% |
| 2022-11-29 | 3 | 9.0 | 3 | 5.40 | 1.07 | 404.67% |
SABS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
SABS's average broker recommendation rating improved by 0 over the prior 44 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SABS as an investment opportunity.
- In the context of all US stocks, SAB BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 1367.36% of them.
- In terms of how SAB BIOTHERAPEUTICS INC fares relative to all US stocks, note that its average analyst price target is higher than 165.95% of that group.
- SAB BIOTHERAPEUTICS INC's number of analysts covering the stock is greater than 217.13% of Healthcare stocks.
- SAB BIOTHERAPEUTICS INC's variance in analysts' estimates is lower than -1025.34% of stocks in the small market cap category.
In the Pharmaceutical Products industry, GRNA, VOR, and FNCH are the three stocks most similar to SAB BIOTHERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is SABS a Buy, Hold or Sell? See the POWR Ratings now!